Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Safety Study of ATI-502 Topical Solution in Subjects With Moderate to Severe Atopic Dermatitis

NCT03585296 is registered in ClinicalTrials.gov with Aclaris Therapeutics, Inc. as lead sponsor.

NCT NCT03585296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03585296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Safety Study of ATI-502 Topical Solution in Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
Aclaris Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 10, 2018
Completion date
April 25, 2019
Enrollment
22 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis